Last reviewed · How we verify
HIP0612
HIP0612 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.
HIP0612 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. Used for FGFR-altered gastric cancer, FGFR-altered urothelial cancer.
At a glance
| Generic name | HIP0612 |
|---|---|
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Drug class | FGFR inhibitor |
| Target | FGFR (Fibroblast Growth Factor Receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
HIP0612 targets FGFR, a receptor tyrosine kinase frequently dysregulated in various cancers through gene amplification, mutation, or translocation. By inhibiting FGFR signaling, the drug suppresses downstream proliferation and survival pathways in FGFR-dependent tumors. This mechanism is particularly relevant in cancers with FGFR alterations, including certain gastric, bladder, and other solid tumors.
Approved indications
- FGFR-altered gastric cancer
- FGFR-altered urothelial cancer
Common side effects
- Hyperphosphatemia
- Diarrhea
- Fatigue
- Nausea
- Stomatitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HIP0612 CI brief — competitive landscape report
- HIP0612 updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI